A Phase 4 interventional study of Dexmedetomidine (DEX) and Placebo in Sepsis and Septic Shock, sponsored by Sichuan Academy of Medical Sciences. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Sichuan Academy of Medical Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing dexmedetomidine in Shock, Septic — 4 open to participants now, 4 under way, 1 of them phase 3. Dexmedetomidine · Shock, Septic.
Among the 11 studies testing dexmedetomidine in Shock, Septic, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 4, and was the 9th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →4 of the 11 studies testing dexmedetomidine in Shock, Septic are open now, in 3 countries. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–90
Hospices Civils de Lyon · Sites in France
Ages 18+
First Affiliated Hospital of Wannan Medical College · Sites in China
Ages 18–85
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 168 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 40 across the 11 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 10 most frequent:
Sichuan Academy of Medical Sciences is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
Sichuan Academy of Medical Sciences has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing dexmedetomidine in Shock, Septic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether early administration of dexmedetomidine can improve autonomic nervous system regulation and clinical outcomes in adult patients with septic shock. It will also evaluate the safety of dexmedetomidine in this population.
The main questions it aims to answer are:
Does early dexmedetomidine improve sympathetic nervous system activity, as measured by heart rate variability (HRV) and blood pressure variability (BPV)?
Does dexmedetomidine reduce endogenous catecholamine levels and vasopressor requirements?
Does early autonomic modulation improve organ function and survival outcomes in septic shock? Researchers will compare dexmedetomidine to a placebo (normal saline) to determine whether dexmedetomidine improves hemodynamic stability and prognosis in patients with septic shock.
Participants will:
Be randomly assigned to receive dexmedetomidine (0.5 μg/kg/h) or placebo by continuous intravenous infusion for 48 hours
Undergo continuous ECG and invasive blood pressure monitoring
Have blood samples collected at predefined time points to measure inflammatory markers and endogenous catecholamine levels
Be assessed for organ function, vasopressor use, and perfusion parameters during the first 48 hours
Be followed up for 28-day and 90-day survival outcomes
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's planned enrollment of 168 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →Sichuan Academy of Medical Sciences is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥ 18 year Septic shock defined by Sepsis-3 criteria Enrollment within 24 hours of diagnosis APACHE II score > 10
Exclusion Criteria:
Pregnancy or lactation Second- or third-degree atrioventricular block Persistent bradycardia (HR \<50 bpm) requiring intervention to dexmedetomidine Norepinephrine dose >0.5 μg/kg/min End-stage disease or \<72 hours Any condition deemed unsuitable by the investigator
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Dexmedetomidine (DEX)
0.5 micrograms per kilogram per hour (0.5 μg/kg/h)
0.9% Sodium Chloride Injection
Heart Rate Variability (HRV)
Heart rate variability will be assessed using continuous electrocardiographic monitoring. The primary HRV parameter analyzed will be the standard deviation of normal-to-normal intervals (SDNN).
Time frame: From enrollment to the end of treatment at 48 hours
Change in Sequential Organ Failure Assessment (SOFA) Score
The change in Sequential Organ Failure Assessment (SOFA) score from baseline to 48 hours will be used to evaluate organ dysfunction.
Time frame: From enrollment to the end of treatment at 48 hours
Interleukin-6 (IL-6) level
Change in plasma IL-6 levels from baseline to 48 hours
Time frame: From enrollment to the end of treatment at 48 hours
ICU length of stay
Duration of ICU stay for each participant
Time frame: From enrollment to ICU discharge or 90 days, whichever occurs first
Duration of Mechanical Ventilation
Total duration of invasive mechanical ventilation during the first 48 hours after enrollment.
Time frame: From randomization until successful liberation from mechanical ventilation, assessed up to 28 days.
Requirement for Renal Replacement Therapy (RRT)
Number of participants requiring renal replacement therapy during the first 48 hours after enrollment.
Time frame: From randomization to 28 days after randomization.
Tumor necrosis factor-α (TNF-α) level
Change in plasma TNF-α levels from baseline to 48 hours
Time frame: From enrollment to the end of treatment at 48 hours
Procalcitonin (PCT) clearance
Percentage change in PCT levels relative to baseline
Time frame: From enrollment to the end of treatment at 48 hours
28-day all-cause mortality
Proportion of participants who die from any cause within 28 days of enrollment
Time frame: From enrollment to 28 days
90-day all-cause mortality
Proportion of participants who die from any cause within 90 days of enrollment
Time frame: From enrollment to 90 days
Incidence of new-onset organ dysfunction
Number of participants developing new organ dysfunction during the study period
Time frame: From enrollment to 90 days or ICU/hospital discharge, whichever occurs first
No study locations are listed for this record.
Plan to share: No
Start is estimated for Mar 2026; primary completion for Mar 2028, 24 months later.
Of 39 non-industry phase 4 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's planned 24 months is close to that.
Counting every sponsor, half of 40 studies reached it within 24 months; a quarter within 16 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Sichuan Academy of Medical Sciences